top of page
  • Writer's pictureMichelle Pugle

Ozempic, Wegovy May Lower Suicide Risk Compared to Similar Drugs, Study Finds

GLP-1 drugs prescribed for weight loss and diabetes are currently under federal investigation.


The Food and Drug Administration (FDA) is “evaluating the need for regulatory action” after the FDA Adverse Event Reporting System (FAERS) received reports of side effects in people using GLP-1 medications like Ozempic, Mounjaro, Zepbound, and Wegovy.


However, a large new study funded by the National Institutes of Health (NIH) found that semaglutide, the active ingredient in Ozempic and Wegovy, is not linked to suicidal thoughts, despite anecdotal claims suggesting otherwise.


Read more in Healthline. Co-authored with Andrea Rice.

Comments


Michelle Pugle, MA

bottom of page